Cargando…

Relationship of inhaled long-acting bronchodilators with cardiovascular outcomes among patients with stable COPD: a meta-analysis and systematic review of 43 randomized trials

Background: Long-acting muscarinic antagonists (LAMAs) and long-acting β2–agonists (LABAs) are the mainstay of maintenance therapy for chronic obstructive pulmonary disease (COPD). Although previous studies have supported inhaled long-acting bronchodilators (ILABs) for overall cardiovascular safety,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Chenxi, Cheng, Wenke, Guo, Jin, Guan, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6489598/ https://www.ncbi.nlm.nih.gov/pubmed/31114181 http://dx.doi.org/10.2147/COPD.S198288

Ejemplares similares

Predicting treatable traits for long-acting bronchodilators in patients with stable COPD
por: Kang, Jieun, et al.
Publicado: (2017)

A new user cohort study comparing the safety of long-acting inhaled bronchodilators in COPD
por: Jara, Michele, et al.
Publicado: (2012)

Long-acting bronchodilators with or without inhaled corticosteroids and 30-day readmission in patients hospitalized for COPD
por: Bishwakarma, Raju, et al.
Publicado: (2017)

Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy
por: Halpin, David M. G., et al.
Publicado: (2016)

Comparison of resource use by COPD patients on inhaled therapies with long-acting bronchodilators: a database study
por: Kozma, Chris M, et al.
Publicado: (2011)

Comparative efficacy of long-acting bronchodilators for COPD - a network meta-analysis
por: Cope, Shannon, et al.
Publicado: (2013)

Effectiveness and safety of concurrent beta-blockers and inhaled bronchodilators in COPD with cardiovascular comorbidities
por: Corrao, Salvatore, et al.
Publicado: (2017)

Cardiovascular morbidity and the use of inhaled bronchodilators
por: Macie, Christine, et al.
Publicado: (2008)

Triple Therapy Versus Dual Bronchodilation and Inhaled Corticosteroids/Long-Acting β-Agonists in COPD: Accumulating Evidence from Network Meta-Analyses
por: Cazzola, Mario, et al.
Publicado: (2019)

Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD
por: Kardos, Peter, et al.
Publicado: (2016)

Risk of adverse cardiovascular events with use of inhaled long-acting bronchodilators in management of chronic obstructive pulmonary disease
por: Wang, Meng-Ting, et al.
Publicado: (2019)

Relationship between FEV(1 )change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review
por: Westwood, Marie, et al.
Publicado: (2011)

Short Term Effects of Tiotropium on COPD Patients Treated with Long Acting Bronchodilators
por: Nicolini, Antonello
Publicado: (2012)

Differential pharmacology and clinical utility of long-acting bronchodilators in COPD – focus on olodaterol
por: Matera, Maria Gabriella, et al.
Publicado: (2015)

Revefenacin: A Once-Daily, Long-Acting Bronchodilator For Nebulized Treatment Of COPD
por: Donohue, James F, et al.
Publicado: (2019)

Long-acting bronchodilators improve exercise capacity in COPD patients: a systematic review and meta-analysis
por: Di Marco, Fabiano, et al.
Publicado: (2018)

Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids
por: Asche, Carl Victor, et al.
Publicado: (2012)

Uncovering the beneficial effects of inhaled bronchodilator in COPD: beyond forced spirometry
por: Neder, José Alberto, et al.
Publicado: (2019)

Correlation Analysis of the Therapy Adherence to Long-Acting Inhalers Among Patients with Stable COPD
por: Tan, Xin, et al.
Publicado: (2023)

Effect of allergic phenotype on treatment response to inhaled bronchodilators with or without inhaled corticosteroids in patients with COPD
por: Cheng, Shih-Lung, et al.
Publicado: (2017)

Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives
por: Rhee, Chin Kook, et al.
Publicado: (2019)

Establishing Quality of Life in Southern Taiwan COPD Patients Using Long-Acting Bronchodilator
por: Chin, Pik-Qi, et al.
Publicado: (2022)

Correction to: Long-acting bronchodilators improve exercise capacity in COPD patients: a systematic review and meta-analysis
por: Di Marco, Fabiano, et al.
Publicado: (2018)

Optimal Bronchodilation for COPD Patients: Are All Long-Acting β(2)-Agonist/Long-Acting Muscarinic Antagonists the Same?
por: Miravitlles, Marc, et al.
Publicado: (2018)

Which bronchodilator in COPD?
por: Russell, Richard, et al.
Publicado: (2007)

COPD: maximization of bronchodilation
por: Nardini, Stefano, et al.
Publicado: (2014)

Prescribing Patterns for Long-Acting Inhaled Bronchodilators Among Rural Adults With Chronic Obstructive Pulmonary Disease
por: Brunner, Wendy M., et al.
Publicado: (2022)

The effects of long-acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease
por: Kliber, Agnes, et al.
Publicado: (2010)

"Show me the money": a fair criticism of economic studies on inhaled bronchodilators for COPD
por: Kostikas, Konstantinos, et al.
Publicado: (2010)

Characteristics of patients with COPD newly prescribed a long-acting bronchodilator: a retrospective cohort study
por: Wurst, Keele E, et al.
Publicado: (2014)

Long-acting bronchodilator use after hospitalization for COPD: an observational study of health insurance claims data
por: Baker, Christine L, et al.
Publicado: (2014)

Treatment of COPD with Long-Acting Bronchodilators: Association Between Early and Longer-Term Clinically Important Improvement
por: Vogelmeier, Claus F, et al.
Publicado: (2021)

Bronchodilators use in patients with COPD
por: Dong, Yaa-Hui, et al.
Publicado: (2015)

Long-acting Inhaled Bronchodilator and Risk of Vascular Events in Patients With Chronic Obstructive Pulmonary Disease in Taiwan Population
por: Tsai, Ming-Jun, et al.
Publicado: (2015)

Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator
por: Singh, Dave, et al.
Publicado: (2020)

Severe COPD Exacerbation Risk and Long-Acting Bronchodilator Treatments: Comparison of Three Observational Data Analysis Methods
por: Roberts, Melissa H., et al.
Publicado: (2015)

An Evaluation Of Single And Dual Long-Acting Bronchodilator Therapy As Effective Interventions In Maintenance Therapy-Naïve Patients With COPD
por: Singh, Dave, et al.
Publicado: (2019)

Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long‐acting bronchodilator‐naïve COPD patients: A pooled analysis
por: Muro, Shigeo, et al.
Publicado: (2019)

Long-acting Inhaled Bronchodilator and Risk of Vascular Events in Patients With Chronic Obstructive Pulmonary Disease in Taiwan Population: Erratum
Publicado: (2016)

Inhaled Long-Acting β2-Agonists Do Not Increase Fatal Cardiovascular Adverse Events in COPD: A Meta-Analysis
por: Xia, Ning, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ol5093lvd0l6kdqv89ln6mcrav